U.S. Markets closed

Ember Therapeutics, Inc. (EMBT)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2750.000 (0.000%)
At close: 10:08AM EDT
People also watch
EPIQCORIDSGXOPNTSRNA

Ember Therapeutics, Inc.

135 East 57th Street
24th Floor
New York, NY 10022
United States
646-406-6243
http://www.embertx.com

Sector
Industry
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Joseph Hernandez M.S.,MBAFounder, Exec. Chairman, Chief Exec. Officer and Chief Financial OfficerN/AN/A44
Dr. Louis A. Tartaglia Ph.D.Chief Exec. Officer, Pres and Member of The Board of DirectorsN/AN/A53
Mr. Michael E. Solomon Ph.D.Chief Operating OfficerN/AN/AN/A
Dr. Dean A. Falb Ph.D.Chief Scientific Officer, Consultant and Scientific AdvisorN/AN/A50
Dr. Jasbir Seehra Ph.D.Chief Scientific Officer and Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport’s syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.

Corporate Governance

Ember Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.